Business Wire

CA-IMPERVA

5.4.2022 14:02:13 CEST | Business Wire | Press release

Share
Imperva Data Security Fabric Provides Bold New Approach to Securing All Data in Multicloud and Hybrid Environments

Imperva, Inc. , (@Imperva ) the comprehensive digital security leader, introduces the Imperva Data Security Fabric (DSF) to modernize and simplify data governance, security, and workflow management for all data across multicloud and hybrid environments. Imperva DSF standardizes data security controls across enterprise environments to provide full visibility of what is happening across all file stores and assets, on-premises, and across clouds. Its flexible architecture supports a wide range of data repositories, ensuring security policies are applied consistently everywhere.

Imperva DSF integrates Imperva Sonar and a deep portfolio of industry-leading and mission critical Imperva Data Security products and technologies. Customers are already using Imperva DSF capabilities to secure data in hundreds of data stores across leading cloud providers. These capabilities provide access to thousands of automation and response integrations to streamline visibility, create specific rules for managing data risk, and leverage a mix of security tools supporting those platforms.

Imperva DSF makes it easier for customers to understand and mitigate data risk at every step of their security journey across structured, semi-structured, and unstructured data. According to Gartner, “by 2024, larger enterprises will triple the unstructured data stored as file or object storage on-premises, at the edge or in the public cloud, compared with 2020. This massive growth in unstructured data demands better protection against threats such as ransomware.1 ” Imperva DSF can discover and classify more than 350 unique file formats, including the most widely used formats by Adobe, Google, Microsoft, and many others. Imperva DSF protects a customer’s multicloud and hybrid environments and provides visibility through a single service that can run anywhere within that environment. Imperva DSF provides a holistic view that makes it easier for customers to quickly identify and secure sensitive information across their entire protected environment.

Across a broad range of areas including policy compliance, compromised credentials, unintentional misuse, and malicious threats to sensitive data, organizations in all industries around the world are asking for our help to protect their data. They need broad but centralized control and automation for a more comprehensive view of risk posture, faster insights to accelerate response times, and reduced cost of ownership,” says Dan Neault, SVP and GM, Data Security, Imperva. “Imperva Data Security Fabric enables organizations to safeguard their sensitive data while ensuring data security, compliance, and privacy, and managing digital risk while confidently moving strategic data to the cloud.”

Imperva DSF and its unique automation capabilities for agent and agentless deployments makes it simpler and lower cost for customers to scale data governance and protection anywhere. "After going through a painful situation with another Data Activity Monitoring solution, we went with Imperva because we needed to deliver something quickly for compliance reasons. Imperva offered us a more efficient agent-based solution in terms of cost, management and a lot less complexity. You get to do everything in a single place,” says Diego Laverde, CISO of Banco Popular Dominicano. “It went into production seamlessly, the business didn’t even realize that it had happened, and it worked as it should.”

Through the Imperva Technology Alliance Program (TAP), Imperva DSF has built-in integrations with the world’s leading hyperscalers (e.g., Amazon Web Services , Microsoft® Azure® , Google Cloud™, etc.), database vendors (e.g., Microsoft® , MongoDB® Atlas, Oracle DBMS, Snowflake , etc.), and workflow managers (e.g., Atlassian, ServiceNow , etc.). Imperva DSF opens up new partner-builder innovation opportunities to provide customers additional capabilities and simplify their orchestration. Imperva TAP is pleased to welcome Mage™ (formerly Mentis), a data masking alternative to Imperva DSF built-in capabilities to help customers secure structured and unstructured data throughout the development lifecycle.

“We are excited about the possibilities Imperva DSF enables for mutual customers and the partner ecosystem,” says Rajesh Parthasarathy, CEO of Mage. “Our technology alliance with Imperva provides organizations with an analyst-recognized integrated masking solution for all data types supported by the Imperva DSF.”

Imperva Data Security Fabric includes:

  • Data Activity Monitoring: mitigate malicious insiders and external threats by detecting changes, auditing activities for compliance, and blocking or alerting on policy violations.
  • Data Risk Analytics: automate detection of non-compliant, risky, or malicious data access behavior across data stores.
  • Data Governance: discover and classify sensitive data residing in structured, semi-structured, and unstructured data types, to operationalize security control policies.
  • Data Access Control: control user rights to sensitive data, including detecting overly-broad data access in the cloud or on-premises.
  • Data Masking: transform data so it is either unreadable or de-identified, allowing processing to happen in compliance.

Additional Information:

GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved

About Imperva

Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.

© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.

1 Gartner Hype Cycle for Storage and Data Protection Technologies, Julie Palmer, 22 July 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye